MolDX: Minimal Residual Disease Testing for Cancer
J15 · Effective Dec 26, 2021
22 active Medicare policies list 0422U, and 5 commercial payer policies list it. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
J15 · Effective Dec 26, 2021
JE · Effective Jan 2, 2022
JF · Effective Jan 2, 2022
JJ · Effective Dec 26, 2021
JM · Effective Dec 26, 2021
J5 · Effective Dec 26, 2021
J8 · Effective Dec 26, 2021
J15 · Effective Oct 1, 2015
JE · Effective Oct 1, 2015
5 policies from 3 payers
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
| Policy | Effective | Status of 0422U |
|---|---|---|
| Concert Genetic Testing Oncology: Hematologic Malignancy | Not recorded | Referenced |
| Concert Genetic Testing Oncology: Solid Tumor Molecular Diagnostics | Not recorded | Referenced |
| Policy | Effective | Status of 0422U |
|---|---|---|
| Genetic Liquid Biopsy in the Management of Cancer and Cancer Surveillance |
JF · Effective Oct 1, 2015
JJ · Effective Oct 1, 2015
JM · Effective Oct 1, 2015
J5 · Effective Feb 16, 2017
J8 · Effective Feb 16, 2017
National · Effective Aug 6, 2026
National · Effective Mar 12, 2026
National · Effective Aug 6, 2026
J5 · Effective Aug 6, 2026
National · Effective Jul 1, 2026
National · Effective Jul 1, 2026
National · Effective Jul 1, 2026
J5 · Effective Jul 1, 2026
| Aug 22, 2026 |
| Covered |
| Genetic Liquid Biopsy in the Management of Cancer and Cancer Surveillance | Jun 14, 2026 | Covered |
|---|
| Policy | Effective | Status of 0422U |
|---|---|---|
| Circulating Tumor DNA and Circulating Tumor Cells for Management (Liquid Biopsy) of Solid Tumor Cancers | Jul 1, 2026 | Covered |